Asciminib, a first-in-class allosteric <i>BCR::ABL1</i> (STAMP) inhibitor, has demonstrated efficacy and favorable tolerability in chronic myeloid leukemia, but its optimal role in Ph+ ALL remains to be defined. Here, BCR is linked to acute lymphoblastic leukemia.